Neurokine Pharmaceuticals Inc. is a development-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic pharmaceutical products. Its research and development activities are focused on assessing known drugs and compounds, developing hypotheses concerning their usage for new indications (diseases), and conducting experimentation and clinical research to test those hypotheses. As of March 12, 2012, the Company had identified three anti-inflammatory products, which included NK001, NK002 and NK-003. NK-001 is an application of the generic drug Etanercept for treating neurocognitive impairment in Coronary Artery Bypass Graft (CABG) surgery patients. NK-002 is a development-stage drug for the treatment of Alzheimer�s disease.